Clinical Development RiskThe stock faces clinical development risk due to the uncertainty surrounding the outcomes of SLN360, SLN124, and SLN501 trials.
Drug Safety ConcernsRusfertide's safety profile raises concerns, as a clinical hold was initiated due to safety findings and the occurrence of secondary malignancies.
Regulatory RiskDespite meeting the primary endpoint in PhII trials, Rusfertide's safety issues in preclinical models and the presence of secondary malignancies may hinder regulatory approval.